透過您的圖書館登入
IP:52.23.201.145
  • 期刊

氟-18去氧葡萄糖正子斷層影造影對於無症狀血清腫瘤標記指數升高復發性乳癌之偵測

18F-FDG-PET to Detect Recurrent Breast Cancer Based on Asymptomatically Elevated Tumor Marker Serum Levels

摘要


Objectives: We aimed to retrospectively evaluate the impact of 18[F] fluorodeoxy-glucose-positron emission tomography (FDG-PET) to detect recurrent breast cancer based on asymptomatically elevated tumor marker levels. Methods: Whole-body FDG-PET was performed on 20 patients suspected of recurrent breast cancer who had increase in asymptomatic tumor markers but with normal imaging modality results. A blood sample was drawn in each case for marker assay (CA15-3 and CEA) on the same day the FDG-PET was to be performed. All of the 20 asymptomatic patients had either a CA15-3>32U/mL or a CEA>5ng/mL. The final diagnosis of recurrent breast cancer was established by operation/biopsy, histopathological findings, or by additional morphologic imaging techniques during clinical follow-up more than l year after initial diagnosis. Results: The final diagnosis of recurrent breast cancer was established in 30 sites of 19 patients. FDG-PET accurately detected 29/30 sites in 18/19 patients with recurrence. The diagnostic sensitivity and accuracy of FDG-PET in patients with suspected recurrent breast cancer and asymptomatically elevated tumor markers were 94.7% and 90.0%, respectively. Conclusions: FDG-PET is a useful technique for detecting recurrent breast cancer suspected by asymptomatically elevated tumor markers levels and has an important clinical impact on the management of these patients.

並列摘要


Objectives: We aimed to retrospectively evaluate the impact of 18[F] fluorodeoxy-glucose-positron emission tomography (FDG-PET) to detect recurrent breast cancer based on asymptomatically elevated tumor marker levels. Methods: Whole-body FDG-PET was performed on 20 patients suspected of recurrent breast cancer who had increase in asymptomatic tumor markers but with normal imaging modality results. A blood sample was drawn in each case for marker assay (CA15-3 and CEA) on the same day the FDG-PET was to be performed. All of the 20 asymptomatic patients had either a CA15-3>32U/mL or a CEA>5ng/mL. The final diagnosis of recurrent breast cancer was established by operation/biopsy, histopathological findings, or by additional morphologic imaging techniques during clinical follow-up more than l year after initial diagnosis. Results: The final diagnosis of recurrent breast cancer was established in 30 sites of 19 patients. FDG-PET accurately detected 29/30 sites in 18/19 patients with recurrence. The diagnostic sensitivity and accuracy of FDG-PET in patients with suspected recurrent breast cancer and asymptomatically elevated tumor markers were 94.7% and 90.0%, respectively. Conclusions: FDG-PET is a useful technique for detecting recurrent breast cancer suspected by asymptomatically elevated tumor markers levels and has an important clinical impact on the management of these patients.

被引用紀錄


程雪敏(2011)。早期乳癌婦女憂鬱程度與生活品質相關因素探討-以中部某區域醫院為例〔碩士論文,中臺科技大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0099-1511201114152020

延伸閱讀